{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/NVCT/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T01:26:12.661Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":7270,"canonical_name":"Nuvectis Pharma, Inc.","cik":"0001875558","uei":null,"lei":null,"duns":null,"ticker":"NVCT"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":24,"clinical":1},"count":25,"timeline":[{"ts":"2026-08-28","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Nuvectis Pharma, Inc. — 2026-08-28","url_slug":"/sec/cik-0001875558/effect/9999999995-26-002815","accession_number":"9999999995-26-002815","importance":30},{"ts":"2026-08-25","kind":"clinical.trial","reporter":"Nuvectis Pharma, Inc.","title":"Study of NXP900 With Lorlatinib in ALK+ Lung Cancer","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07784959","excerpt":"[\"ALK Positive\",\"ALK Positive Non-small Cell Lung Cancer\",\"NSCLC\",\"ALK+ Non-Small-Cell Lung Carcinoma\"]","importance":30},{"ts":"2026-08-21","kind":"sec.filing","form_type":"8-K","title":"8-K — Nuvectis Pharma, Inc. — 2026-08-21","url_slug":"/sec/cik-0001875558/8-k/0001104659-26-099712","accession_number":"0001104659-26-099712","importance":35},{"ts":"2026-08-21","kind":"sec.filing","form_type":"S-3","title":"S-3 — Nuvectis Pharma, Inc. — 2026-08-21","url_slug":"/sec/cik-0001875558/s-3/0001104659-26-099717","accession_number":"0001104659-26-099717","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Nuvectis Pharma, Inc. — 2026-08-06","url_slug":"/sec/cik-0001875558/schedule-13g/0001213900-26-085988","accession_number":"0001213900-26-085988","importance":55},{"ts":"2026-08-05","kind":"sec.filing","form_type":"4","title":"4 — Nuvectis Pharma, Inc. — 2026-08-05","url_slug":"/sec/cik-0001875558/4/0001104659-26-091279","accession_number":"0001104659-26-091279","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Nuvectis Pharma, Inc. — 2026-08-04","url_slug":"/sec/cik-0001875558/10-q/0001104659-26-090109","accession_number":"0001104659-26-090109","importance":45},{"ts":"2026-08-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Nuvectis Pharma, Inc. — 2026-08-04","url_slug":"/sec/cik-0001875558/8-k/0001104659-26-090094","accession_number":"0001104659-26-090094","importance":35},{"ts":"2026-08-03","kind":"sec.insider.a","reporter":"Carson Michael J.","title":"Vice President, Finance","shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.p","reporter":"Mosseri Marlio Charles","title":"","shares":50000,"price_per_share":18.32,"usd_value":916000,"security_title":"Common Stock","importance":50.916},{"ts":"2026-06-30","kind":"sec.insider.p","reporter":"BENTSUR RON","title":"Chairman & CEO","shares":12500,"price_per_share":20,"usd_value":250000,"security_title":"Common Stock","importance":50.25},{"ts":"2026-06-30","kind":"sec.filing","form_type":"8-K","title":"8-K — Nuvectis Pharma, Inc. — 2026-06-30","url_slug":"/sec/cik-0001875558/8-k/0001104659-26-079360","accession_number":"0001104659-26-079360","importance":35},{"ts":"2026-06-30","kind":"sec.filing","form_type":"424B5","title":"424B5 — Nuvectis Pharma, Inc. — 2026-06-30","url_slug":"/sec/cik-0001875558/424b5/0001104659-26-079359","accession_number":"0001104659-26-079359","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Nuvectis Pharma, Inc. — 2026-06-29","url_slug":"/sec/cik-0001875558/8-k/0001104659-26-078823","accession_number":"0001104659-26-078823","importance":35},{"ts":"2026-06-29","kind":"sec.filing","form_type":"424B5","title":"424B5 — Nuvectis Pharma, Inc. — 2026-06-29","url_slug":"/sec/cik-0001875558/424b5/0001104659-26-078864","accession_number":"0001104659-26-078864","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"8-K","title":"8-K — Nuvectis Pharma, Inc. — 2026-06-23","url_slug":"/sec/cik-0001875558/8-k/0001104659-26-076624","accession_number":"0001104659-26-076624","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Nuvectis Pharma, Inc. — 2026-06-12","url_slug":"/sec/cik-0001875558/8-k/0001104659-26-073419","accession_number":"0001104659-26-073419","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Nuvectis Pharma, Inc. — 2026-06-12","url_slug":"/sec/cik-0001875558/4/0001104659-26-073455","accession_number":"0001104659-26-073455","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Nuvectis Pharma, Inc. — 2026-06-12","url_slug":"/sec/cik-0001875558/4/0001104659-26-073459","accession_number":"0001104659-26-073459","importance":30},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Oliviero James F III","title":"","shares":35000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Hoberman Kenneth","title":"","shares":35000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Sanchez Juan","title":"","shares":35000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Kaplan Matthew L.","title":"","shares":35000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Nuvectis Pharma, Inc. — 2026-04-27","url_slug":"/sec/cik-0001875558/def-14a/0001104659-26-049476","accession_number":"0001104659-26-049476","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Nuvectis Pharma, Inc. — 2026-04-27","url_slug":"/sec/cik-0001875558/defa14a/0001104659-26-049480","accession_number":"0001104659-26-049480","importance":30}]}